Journal article

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Tomas Kalincik, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Marco Onofrj, Alessandra Lugaresi, Serkan Ozakbas, Ludwig Kappos, Jens Kuhle, Murat Terzi, Jeannette Lechner-Scott, Cavit Boz, Francois Grand'Maison, Julie Prevost, Patrizia Sola, Diana Ferraro Show all

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | BMJ PUBLISHING GROUP | Published : 2019

Abstract

OBJECTIVE: Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. METHODS: We identified all patients with relapsing-remitting multiple sclerosis treated with teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence and disability follow-up in the global MSBase cohort study. Patients were matched using propensity scores. Three pairwise analyses compared annualised relapse rates and hazards of disability accumulation, disability improvement and treatment discontinuation (analysed with negative binomial models and weighted conditional survival model..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

This study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766, 1080518). The MS Base Foundation is a not-for-profit organisation that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.